Edwards Lifesciences (EW) Research & Development (2009 - 2026)

Edwards Lifesciences has reported Research & Development for 18 years, with the latest figure at $263.3 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 3.42% year-over-year to $263.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 3.52% YoY), and the FY2025 full-year result was $1.1 billion, up 2.49% from the prior year.
• Research & Development for Q1 2026 stood at $263.3 million, down from $267.7 million in the prior quarter.
• The five-year high for Research & Development was $280.7 million in Q3 2025, with the low at $130.6 million in Q4 2022.
• Average Research & Development over 5 years is $248.8 million, with a median of $254.6 million recorded in 2025.
• Year-over-year, Research & Development slumped 43.9% in 2022 and jumped 85.38% in 2023.
• Tracing EW's Research & Development over 5 years: stood at $130.6 million in 2022, then surged by 85.38% to $242.1 million in 2023, then grew by 11.98% to $271.1 million in 2024, then fell by 1.25% to $267.7 million in 2025, then declined by 1.64% to $263.3 million in 2026.
• The last three Research & Development figures came in at $263.3 million (Q1 2026), $267.7 million (Q4 2025), and $280.7 million (Q3 2025), per Business Quant data.

Peer Comparison